Stockreport

MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting [Yahoo! Finance]

MorphoSys AG - American Depositary Shares  (MOR) 
PDF PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety data from the Phase 3 MANIFE [Read more]